<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carbidopa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carbidopa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carbidopa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11487" href="/d/html/11487.html" rel="external">see "Carbidopa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F146016"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lodosyn</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F146022"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Decarboxylase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F146017"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f01595c-b615-45af-983e-0a196d0c3f4f">Parkinsonism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinsonism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients receiving carbidopa/levodopa therapy, a carbidopa dose ≥75 mg/day may be necessary to decrease the risk of adverse effects from peripheral dopamine (Hoehn 1980; Kaakkola 1985).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carbidopa augmentation in patients receiving carbidopa-levodopa:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients receiving carbidopa/levodopa 10/100: <b>Oral:</b> 25 mg daily with first daily dose of carbidopa/levodopa; if necessary, 12.5 to 25 mg may be given with each subsequent dose of carbidopa/levodopa; maximum: 200 mg/day (including from carbidopa/levodopa)</p>
<p style="text-indent:-2em;margin-left:6em;">Patients receiving carbidopa/levodopa 25/250 or carbidopa/levodopa 25/100: <b>Oral: </b>25 mg with any dose of carbidopa/levodopa throughout the day; maximum: 200 mg/day (including from carbidopa/levodopa)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy</b>: Discontinuation of carbidopa/levodopa therapy may result in neuroleptic malignant-like syndrome (Grimes 2019). Avoid sudden discontinuation or rapid dose reduction; some experts recommend a gradual taper over several weeks or more (Oliver 2021).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block doe drugH1Div" id="F146018"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F145997"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions are associated with concomitant administration with levodopa in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, chest pain, edema, flushing, hypertension, hypotension, orthostatic hypotension, palpitations, phlebitis, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, bullous rash (including bullous pemphigoid), dark sweat, diaphoresis, malignant melanoma, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal lactate dehydrogenase, decreased serum potassium, hot flash, hyponatremia (Shihabudheen 2020), increased libido (including hypersexuality), increased serum glucose, increased uric acid, pyridoxine deficiency (Wise 2022), weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, anorexia, bruxism, constipation, dark saliva, diarrhea, duodenal ulcer, dysgeusia, dyspepsia, dysphagia, flatulence, gastrointestinal hemorrhage, gastrointestinal pain, glossopyrosis, heartburn, hiccups (Shihabudheen 2020), nausea, sialorrhea, sore throat, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bacteriuria, dark urine, glycosuria, hematuria, priapism, proteinuria, pyuria, urinary frequency, urinary incontinence, urinary retention, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal Coombs' test, agranulocytosis, anemia, decreased hematocrit, decreased hemoglobin, hemolytic anemia (Bernstein 1979), Henoch-Schonlein purpura (Niedermaier 1997), leukocytosis, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal alanine aminotransferase, abnormal aspartate transaminase, abnormal bilirubin levels, alkaline phosphatase abnormal</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (including nightmares), aggressive behavior, agitation, asthenia, confusion, dementia, depression (including depression with suicidal tendencies) (Ayobello 2019), disorientation, dizziness, drowsiness, fatigue, headache, impulse control disorder (including pathological gambling), insomnia, malaise, neuroleptic malignant syndrome (Perry 2012), on-off phenomenon (Raja 2020), paresthesia, psychosis (including delusion, hallucination, paranoid ideation) (Hinkle 2018), sense of stimulation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, dyskinesia (including choreiform movements, dystonic reaction, and other involuntary body movements), lower leg pain, muscle cramps, shoulder pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, mydriasis, oculogyric crisis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea, hoarseness, irregular breathing, upper respiratory tract infection</p></div>
<div class="block coi drugH1Div" id="F146007"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to carbidopa or any component of the formulation; use of nonselective MAO inhibitor therapy with or within prior 14 days (however, may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B); narrow-angle glaucoma</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F145994"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Observe patients closely for development of depression with concomitant suicidal tendencies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dyskinesias: May cause or exacerbate dyskinesias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impulse control disorders: Antiparkinson therapy has been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), urges to spend money uncontrollably, and/or binge eating. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic effects: May cause hallucinations and psychotic-like behavior.</p>
<p style="text-indent:-2em;margin-left:4em;">• Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or preexisting sleep disorder; caution with concomitant sedating medication; consider discontinuing if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic disorders: Avoid use in patients with major psychotic disorder.</p></div>
<div class="block foc drugH1Div" id="F146002"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lodosyn: 25 mg [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p></div>
<div class="block geq drugH1Div" id="F145990"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F146008"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Carbidopa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.75 - $21.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lodosyn Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $35.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F146004"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with meals to decrease GI upset.</p></div>
<div class="block use drugH1Div" id="F146003"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinsonism: </b>Given with carbidopa/levodopa in the treatment of idiopathic Parkinson disease, postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide and/or manganese intoxication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Administration of carbidopa allows use of a lower dosage of levodopa, more rapid titration, and a decrease in nausea and vomiting associated with levodopa. Use with carbidopa/levodopa in patients requiring additional carbidopa; carbidopa has no effect without levodopa.</p></div>
<div class="block mst drugH1Div" id="F3245270"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lodosyn [US] may be confused with Lidosen brand name for lidocaine [Italy]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298969"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F145998"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spiramycin: May decrease the serum concentration of Carbidopa. And thus may decrease the effectiveness of levodopa.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13276948"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Carbidopa can be detected in the umbilical cord but absorption in fetal tissue is minimal (Merchant 1995). The incidence of Parkinson disease in pregnancy is relatively rare and information related to the use of carbidopa in pregnant women is limited to use with other agents. Refer to the carbidopa and levodopa monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F20609426"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if carbidopa is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F146009"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with meals to decrease GI upset.</p></div>
<div class="block mop drugH1Div" id="F13457241"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, LFTs, renal function; BP, mental status; signs and symptoms of neuroleptic malignant syndrome if abrupt discontinuation required (as with surgery); periodic intraocular pressure (in patients with wide-angle glaucoma).</p></div>
<div class="block pha drugH1Div" id="F145993"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Carbidopa is a decarboxylase inhibitor with little or no pharmacological activity when given alone in usual doses. Unlike levodopa, carbidopa does not cross the blood-brain barrier and only inhibits the decarboxylation of peripheral levodopa to dopamine. Coadministration of carbidopa with levodopa allows for higher central nervous system concentrations of dopamine with lower doses of levodopa. Reduced peripheral formation of dopamine also reduces peripheral adverse reactions, including nausea and vomiting.</p></div>
<div class="block phk drugH1Div" id="F146006"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;text-align:justify;display:inline">Distribution: Does not cross the blood-brain barrier</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56519512"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lodosyn</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31032135">
<a name="31032135"></a>Ayobello A, Saway B, Greenage M. Attempted suicide in a Parkinsonian patient treated with DBS of the VIM and high dose carbidopa-levodopa. <i>Case Rep Psychiatry</i>. 2019;2019:2903762. doi:10.1155/2019/2903762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/31032135/pubmed" id="31032135" target="_blank">31032135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-466061">
<a name="466061"></a>Bernstein RM. Reversible haemolytic anaemia after levodopa-carbidopa. <i>Br Med J</i>. 1979;1(6176):1461-1462. doi:10.1136/bmj.1.6176.1461-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/466061/pubmed" id="466061" target="_blank">466061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31501181">
<a name="31501181"></a>Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. <i>CMAJ</i>. 2019;191(36):E989-E1004. doi:10.1503/cmaj.181504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/31501181/pubmed" id="31501181" target="_blank">31501181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29756003">
<a name="29756003"></a>Hinkle JT, Perepezko K, Bakker CC, et al. Onset and remission of psychosis in Parkinson's disease: pharmacologic and motoric markers. <i>Mov Disord Clin Pract</i>. 2018;5(1):31-38. doi:10.1002/mdc3.12550<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/29756003/pubmed" id="29756003" target="_blank">29756003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7356419">
<a name="7356419"></a>Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. <i>Arch Neurol</i>. 1980;37(3):146-149. doi:10.1001/archneur.1980.00500520044006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/7356419/pubmed" id="7356419" target="_blank">7356419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4082903">
<a name="4082903"></a>Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. <i>Acta Neurol Scand</i>. 1985;72(4):385-391. doi:10.1111/j.1600-0404.1985.tb00888.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/4082903/pubmed" id="4082903" target="_blank">4082903</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lodosyn (carbidopa) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8527007">
<a name="8527007"></a>Merchant CA, Cohen G, Mytilineou C, et al, "Human Transplacental Transfer of Carbidopa/Levodopa," <i>J Neural Transm Park Dis Dement Sect</i>, 1995, 9(2-3):239-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/8527007/pubmed" id="8527007" target="_blank">8527007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9107252">
<a name="9107252"></a>Niedermaier G, Briner V. Henoch-Schönlein syndrome induced by carbidopa/levodopa. <i>Lancet</i>. 1997;349(9058):1071-1072. doi:10.1016/S0140-6736(05)62294-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/9107252/pubmed" id="9107252" target="_blank">9107252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oliver.1">
<a name="Oliver.1"></a>Oliver D, Veronese S. Palliative approach to Parkinson disease and parkinsonian disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22613365">
<a name="22613365"></a>Perry D, Birthi P, Salles S, McDowell S. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy. <i>PM R</i>. 2012;4(5):383-384. doi:10.1016/j.pmrj.2011.11.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/22613365/pubmed" id="22613365" target="_blank">22613365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33145134">
<a name="33145134"></a>Raja K, Ramrakhia S, Dev K, et al. The risk factors for the wearing-off phenomenon in Parkinson's disease. <i>Cureus</i>. 2020;12(9):e10729. doi:10.7759/cureus.10729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/33145134/pubmed" id="33145134" target="_blank">33145134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32509684">
<a name="32509684"></a>Shihabudheen P, Anver PC, Uvais NA, Mohammed TP. Dose-dependent L-dopa/carbidopa-induced hyponatremia presenting with hiccups. <i>J Family Med Prim Care</i>. 2020;9(3):1749-1751. doi:10.4103/jfmpc.jfmpc_1044_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/32509684/pubmed" id="32509684" target="_blank">32509684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35949204">
<a name="35949204"></a>Wise A, Lemus HN, Fields M, Swan M, Bressman S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa. <i>Case Rep Neurol</i>. 2022;14(2):291-295. doi:10.1159/000525234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carbidopa-drug-information/abstract-text/35949204/pubmed" id="35949204" target="_blank">35949204</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9200 Version 179.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
